69 results about "Breath test" patented technology

The alkane profile (FIGS. 12-14) comprising the alveolar gradients of n-alkane in breath having 4 carbons to 20 carbons, and the methyl alkane profile (FIGS. 30-34) are determined for the diagnosis of disease in mammals, including humans.

A breath test for diagnosing the presence of Helicobacter pylori in a subject is described. The method of diagnosing Helicobacter pylori is performed as follows. First, a safe and effective amount of urea, preferably appropriately labelled, is administered to the subject. Second, a plurality of the exhaled breaths of the subject is analyzed to detect the concentration of a cleavage product or products, produced when urease cleaves the substrate. The measured concentrations are then fitted to a curve, and the derivative is then calculated, to indicate the presence or absence of Helicobacter pylori infection in the subject.

The alkane profile, comprising the alveolar gradients of n-alkanes in breath having 4 to 20 carbons, is determined for the diagnosis of disease in mammals, including humans.

The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut. An H2S or lactulose breath test and/or detection of H2S or thiosulfate in the blood or urine may be used as a diagnostic and/or prognostic for assessing a systemic H2S load that exceeds a mammal's natural detoxification capacity. These tests may similarly be used to monitor the effectiveness of a therapeutic intervention for SIBO and/or the diseases or physiologic conditions whose pathology is linked thereto. Because SIBO is related to hyperhomocysteinemia, diseases and physiologic conditions that relate to hyperhomocysteinemia may further be monitored and treated in connection with the methods of the present invention.

A tool for telemedicine including an improved breath collection system of human breath to facilitate the analysis of volatile organic components (VOCs) contained in human breath in which breath tests can be performed at remote sites for rapid detection of different diseases. The system can include a standoff breath collection device including an arcuate structure for concentration and analysis of volatile organic components (VOCs) at the point-of-use that avoids the use of mouthpieces found in conventional breath collection apparatuses.

The invention relates to a system for breath test of a person. It includes a sensor unit configured to sense the presence/concentration of a volatile substance, e.g. alcohol, present in air flowing through a predefined inlet area and generating a signal corresponding to the concentration of said substance. An analyzer determines the concentration of said substance in the breath of said person. It comprises means for the temporary interruption of said air flow at a point in time coinciding with the detection of a breath. It also relates to a method comprising interrupting the flow through said predefined area for a predetermined period of time, and detecting the concentration of said substance during said interruption.

A calibration checking device, and methods of mandating its use at regular time intervals, to ensure maintenance of the accuracy of gas analyzers, especially for use with breath tests, Each calibration checking device is designed to be used for a predetermined number of tests. After first connection of a new calibration checking device, a volume of known calibration checking gas is released into the instrument, and a calibration checking measurement is initiated. A signal is sent to a counting mechanism which both enables the use of the instrument, and commences a count of the number of tests performed by the breath tester. When the number of tests is exceeded, the instrument is disenabled. The device can include a moisture filter having an interface with the instrument, which prevents its operation if the filter is used beyond the recommended number of times, or if excess moisture renders it saturated.

A breath test system is provided comprising a sensor unit configured to sense the presence or concentration of a volatile substance present in air flowing through a predefined inlet area, and generate a signal corresponding to the concentration of said substance. Also provided is an apparatus configured to detect the presence of a person in the vicinity of said input area, and registering said presence, and configured to respond by delivering an output. This apparatus includes a unit configured to call for immediate attention of said person, and upon registration of the presence of said person, provide instructions to said person to direct an expiratory air flow towards said inlet area. An analyzer to determine breath substance concentration of said person is also provided, the determination based on said signal corresponding to the substance concentration.

A breath test simulator for supplying a breath test analyzer with a vapor including ethyl alcohol includes a heated thermal mass to heat an inlet passage.

The invention provides a breath testing device which visually indicates the presence of ammonia in a patient's breath, in particular ammonia from helicobacter pylori urease infection. The breath testing device comprises a visual indicating agent which changes color in response to ammonia odors, such as 4,4′-bis(dimethylamino)-benzhydrol (Michler's hydrol or BDMB), pararosaniline base and alpha-naphtholbenzein. The indicating agent is applied to a substrate which is then inserted into a tube or straw, which can be attached to the inlet of a breath collection balloon. When the patient blows into the tube or straw, the indicating agent will change color if it detects levels of ammonia which are consistent with helicobacter pylori urease infection.

The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of ¹³CO₂ exhaled by a the subject upon intravenous or oral administration of a ¹³C-labeled CYP2D6 substrate compound. The present invention is useful as an in vivo phenotype assay for evaluating CYP2D6-related activity using the metabolite ¹³CO₂ in expired breath and to determine the optimal dosage and timing of administration of CYP2D6 substrate compound.

A drug interlock for vehicles based on exhaled breath directed onto said SERS-active substrate, wherein a detected drug substance in exhaled breath of a subject locks said vehicle from use for at least a pre-determined time or a repeated exhaled breath test where no drugs are detected. A collecting surface has a Surface Enhanced Raman Spectroscopy (SERS)-active layer that comprises at least one SERS-active material. The collecting surface is arranged as an outer surface of a waveguide for contact with exhaled breath, such that at least traces of said at least one drug substance in said exhaled breath can contact said SERS-active layer for read-out of a Raman shift spectrum that is detected in-situ for said detecting the presence or determining the quantitative amount of said at least one drug substance from said exhaled breath.

A breath test and kit for performing the breath test are described for the diagnosis of diabetic indications and monitoring of glycemic control. The breath test utilizes the measurement of expired 13C-labeled CO2 following the ingestion of a 13C-enriched glucose source.

Methods of determining gastro-intestinal conditions by performing a succession of breath tests or others tests, particularly for determining the gastric emptying or gastric accomodation condition of a subject. Methods of performing successive gastric emptying tests with different test meals are also presented, enabling the gastric accommodation to be determined. The effects of different test means on the results is presented. Novel substrates for use in such tests are suggested, including the use of micro-encapsulation. Breath tests for the detection of bacterial overgrowth, lactose intolerance and combinations thereof are presented.

Methods for assessing an overall digestive health of a patient are provided, which include administering a breath test that uses a label incorporated into proteins, carbohydrates, and lipids and further incorporating the labeled material into a meal which, when cooked, facilitates the binding of the label material to the solid phase matrix of the meal. Methods for assessing digestive functions of a patient are also provided, which includes concurrently administering a breath test and a scintigraphy test that measure gastric emptying in a stomach.

A breath simulator for supplying a breath test analyzer with a sample effluent of ethyl alcohol that controls headspace and adjacent effluent passageway temperature.

The present invention relates to methods and systems for diagnosis, prognosis and monitoring of hepatocellular carcinoma (HCC). Specifically, the present invention relates to the use of breath tests based on isotope-labeled octanoate in the detection and monitoring of HCC.

The present invention provides a test meal kits that are used in the diagnosis of gastrointestinal disorders characterized by changes in the rate of gastric emptying; and, with a breath test or a nuclear scintigraphy scan, are used to measure a half-gastric emptying time useful for therapy monitoring of gastrointestinal disorders in clinical.

The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of ¹³CO₂ exhaled by the subject upon intravenous or oral administration of a ¹³C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite ¹³CO₂ in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.